GERM — ETFMG Treatments Testing and Advancements ETF
Data updated: 2024-02-28
GERM — ETFMG Treatments Testing and Advancements ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Materials Equity · $12.78M AUM · 0.68% expense ratio · -13.8% 1-yr return. From SEC regulatory filings.
GERM Fund Overview
GERM — ETFMG Treatments Testing and Advancements ETF is a US mutual fund managed by ETF Managers Trust, categorised as United States Materials Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: ETF Managers Trust
- Category: United States Materials Equity
- Assets under management: $12.78M
- 1-year return: -13.8%
- Ticker: GERM
- SEC CIK: 0001467831
- SEC series ID: S000068972
- Share class ID: C000220417
GERM Holdings
Top 10 holdings of ETFMG Treatments Testing and Advancements ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Mount Vernon Liquid Assets Portfolio, LLC | 29.95% |
| Moderna Inc | 6.83% |
| Alnylam Pharmaceuticals Inc | 6.07% |
| BioNTech SE | 5.61% |
| Laboratory Corp of America Hol | 5.59% |
| Quest Diagnostics Inc | 5.36% |
| ImmunityBio Inc | 4.85% |
| Immunocore Holdings PLC | 4.61% |
| Vaxcyte Inc | 4.31% |
| QuidelOrtho Corp | 3.81% |
GERM Portfolio Allocation
Asset-class allocation of ETFMG Treatments Testing and Advancements ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.4% |
| Cash & Equivalents | 30.7% |
GERM Performance
Total returns for GERM (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -13.8% |
| 3 years (annualised) | -13.6% |
GERM Risk Information
Risk metrics for GERM, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 23.8%
GERM Costs and Fees
GERM costs about $68 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.68%
- Gross expense ratio: 0.68%
- Portfolio turnover: 30%
- Brokerage commissions: 16.03 bps of average net assets (SEC N-CEN)
GERM Cashflows
Over the 12 months to 2023-12, ETFMG Treatments Testing and Advancements ETF had net inflows of $8.38M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2023-12 | $900.88K |
| 2023-11 | $877.24K |
| 2023-10 | $0 |
| 2023-09 | $0 |
| 2023-08 | $1.01M |
| 2023-07 | $1.04M |
GERM Debt Constituents
No individual debt constituents are reported in ETFMG Treatments Testing and Advancements ETF's latest SEC N-PORT filing.
GERM Prospectus and SEC Filings
Official ETFMG Treatments Testing and Advancements ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Materials Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.